Adamis Pharmaceuticals Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADMP research report →
Companywww.adamispharmaceuticals.com
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19.
- CEO
- Ebrahim Versi
- IPO
- 1995
- Employees
- 11
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $7.25M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -60.93%
- Op Margin
- -526.88%
- Net Margin
- -556.72%
- ROE
- -209.88%
- ROIC
- 20462.31%
Growth & Income
- Revenue
- $4.76M · 115.34%
- Net Income
- $-26,199,406 · 24.28%
- EPS
- $-12.24 · 27.14%
- Op Income
- $-25,058,966
- FCF YoY
- 31.86%
Performance & Tape
- 52W High
- $21.70
- 52W Low
- $0.45
- 50D MA
- $0.90
- 200D MA
- $6.11
- Beta
- 1.28
- Avg Volume
- 3.11M
Get TickerSpark's AI analysis on ADMP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 23, 23 | Dorbin John W. Jr. | other | 70,000 |
| Oct 23, 23 | Dorbin John W. Jr. | other | 0 |
| Oct 16, 23 | COHEN SETH | other | 151,416 |
| Oct 16, 23 | COHEN SETH | other | 0 |
| Sep 15, 23 | Versi Ebrahim | other | 729,200 |
| Sep 15, 23 | Versi Ebrahim | other | 729.2 |
| May 25, 23 | Versi Ebrahim | other | 177,194 |
| May 25, 23 | Versi Ebrahim | other | 20,577 |
| May 25, 23 | Versi Ebrahim | other | 8,745 |
| May 25, 23 | Versi Ebrahim | other | 1,941.2 |
Our ADMP Coverage
We haven't published any research on ADMP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ADMP Report →